Equillium Inc(EQ) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.2 | Insider Own | 20.17% | Shs Outstand | 63.4M | Perf Week | 11.38% |
| Market Cap | 0.09B | Forward P/E | - | EPS next Y | -10.24% | Insider Trans | -3.08% | Shs Float | 50.6M | Perf Month | -11.04% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | -0.05 | Inst Own | 58.65% | Short Float | 11.17% | Perf Quarter | -37.73% |
| Income | -0.02B | P/S | - | EPS this Y | 47.44% | Inst Trans | -3.13% | Short Ratio | 9.77 | Perf Half Y | -34.13% |
| Sales | 0.00B | P/B | 1.55 | EPS next 5Y | 11.09% | ROA | -50.68% | Short Interest | 5.66M | Perf YTD | -11.61% |
| Book/sh | 0.88 | P/C | 1.52 | EPS past 3/5Y | 40.45% 23.22% | ROE | -58.98% | 52W High | -61.3% ($3.54) | Perf Year | -3.52% |
| Cash/sh | 0.9 | P/FCF | - | Sales past 3/5Y | - | ROIC | -32.05% | 52W Low | 81.17% ($0.76) | Perf 3Y | 158.83% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 64.23% | Gross Margin | - | Volatility(W/M) | 8.22% 9.89% | Perf 5Y | -78.29% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.13 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 23.4 | EPS Q/Q | 73.86% | Profit Margin | - | RSI (14) | 43.79 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 23.4 | Sales Q/Q | - | SMA20 | 1.11% ($1.35) | Beta | 2.04 | Target Price | $8.6 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/13 | SMA50 | -22.42% ($1.77) | Rel Volume | 0.54 | Prev Close | $1.42 |
| Employees | 14 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 25.93% - | SMA200 | -34.09% ($2.08) | Avg Volume(3M) | 0.58M | Price | $1.37 |
| IPO | 2018/10/12 | Option/Short | Yes/Yes | Trades | 1291 | Volume | 310,515 | Change | -3.52% |
🧬 Equillium is a US clinical-stage biotechnology company that targets immune and inflammatory diseases. Its core candidate is the monoclonal antibody itolizumab, which has a differentiated mechanism that modulates signaling pathways of immune cell surface receptors to suppress pathogenic T effector cells while preserving regulatory T cells. The company is centered around a novel drug pipeline that has primarily been developed for immune-mediated diseases such as graft-versus-host disease.
Over the past 1 year, on the lower side
61% below its 1-year high.
Traded less than usual. That is 54% of its average volume.
EQ has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +47.4% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -78.3%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 58.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IWC iShares Micro-Cap ETF <0.01% 
AVSC Avantis U.S Small Cap Equity ETF <0.01% 
DFAS U.S. Small Cap Portfolio-ETF Class Shares <0.01% 
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
VOO Vanguard S&P 500 ETF 1063.6B 
IVV iShares Core S&P 500 ETF 886.1B 
SPY SPDR S&P 500 ETF Trust 813.6B VTI Vanguard Morningstar Total Stock Market ETF 701.3B 
QQQ Invesco QQQ Trust Series 1 480.9B It ranks #370 of 595 in the industry
Based on market cap of $87M.
FAQ
What kind of company is EQ?
EQ belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of EQ?
The market cap of EQ is approximately $87M, ranking 4,543 within its sector.
What is the 52-week high and low for EQ?
EQ has recorded a 52-week high of $3.54 and a low of $0.76.
